MEG3 and myeloid sarcoma: MS treatment involves various components, primarily disease-modifying therapies (DMTs), which playing a primary role in effectively reducing intensity, progression, relapses, disability, and maintain life quality [24].This study investigates the expression levels and diagnostic importance of MEG3, T-bet, and IFN-γ in untreated and treated individuals with 4 different DMTs including Glatiramer acetate (GA), Fingolimod, Dimethyl fumarate (DMF) and, Interferon beta-1alpha (IFNβ-1a).